Targeted Demethylation to Enhance Response or Overcome Resistance to EGFR Blocking Agents in KRAS Wild-Type Metastatic Colorectal Cancer Patients Using Sequential Decitabine and Panitumumab.

Trial Profile

Targeted Demethylation to Enhance Response or Overcome Resistance to EGFR Blocking Agents in KRAS Wild-Type Metastatic Colorectal Cancer Patients Using Sequential Decitabine and Panitumumab.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2013

At a glance

  • Drugs Decitabine (Primary) ; Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov record.
    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top